Literature DB >> 9894248

p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up.

A Vital1, H Loiseau, G Kantor, V Daucourt, G Chene, F Cohadon, A Rougier, J Rivel, C Vital.   

Abstract

p53 protein expression was evaluated by immunohistochemistry in a homogeneous series of 100 supratentorial grade II astrocytomas with long-term follow-up. The staining was positive in 72 cases. The proportion of p53 positive tumors was slightly higher in younger patients. The tumor regrowths which derived from p53 positive tumors were themselves p53 positive, and this p53 immunopositivity was often stronger than in the initial tumors. All of the 10 gemistocytic astrocytomas included in our series were p53 positive, and age more than histological type appeared decisive in prognosis. p53 protein expression did not quite reach statistical significance as an independent predictive variable in multivariate analysis, whereas survival was related with age, mass effect, surgery and tumor location. Only a tendency to a longer survival was observed on the curves in younger patients with mildly positive tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9894248     DOI: 10.1016/S0344-0338(98)80085-X

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Gemistocytes in astrocytomas: are they a significant prognostic factor?

Authors:  Dely C Martins; Suzana M Malheiros; Lucila H Santiago; João N Stávale
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

Review 2.  P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature.

Authors:  Georgia Levidou; Elias El-Habr; Angelica A Saetta; Christine Bamias; Klea Katsouyanni; Klea Katsougiannis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  J Neurooncol       Date:  2010-05-12       Impact factor: 4.130

3.  Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.

Authors:  Wei-Ying Yue; Ke Sai; Qiu-Liang Wu; Yun-Fei Xia; Su-Huan Yu; Zhong-Ping Chen
Journal:  Chin J Cancer       Date:  2012-02-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.